Louisiana picks Gilead to partner on 'Netflix' model for hep C drugs by Eric Sagonowsky Wednesday, March 27, 2019 Louisiana is the first state to adopt a subscription model for prescription drug purchasing—and it's starting out with Gilead's hep C drugs.
AbbVie, Gilead and Merck bid on 'Netflix' deal for hep C meds by Eric Sagonowsky Thursday, March 7, 2019 Louisiana is moving forward with a novel method of purchasing hepatitis C drugs, and so far, industry players are on board.
Washington eyes 'winner take all' deal for hep C drugs by Eric Sagonowsky Monday, January 28, 2019 Washington plans to treat tens of thousands of hepatitis C patients on state-purchased health insurance.
Louisiana seeking comments on 'Netflix' model for hep C drugs by Eric Sagonowsky Thursday, August 16, 2018 Louisiana has proposed a "subscription-based payment model" for hepatitis C drugs it hopes can benefit the state and drugmakers alike.
Pharma mobilizes lobbyists to buck state action on drug prices by Jay Hancock and Shefali Luthra, Kaiser Health News Thursday, February 1, 2018 With federal officials failing to come up with legislation to control drug prices, that task is moving to the states—and so is pharma muscle.
Pfizer strikes settlement with Louisiana AG for $1M of naloxone by Arlene Weintraub Tuesday, May 16, 2017 When Louisiana AG Jeff Landry inherited an antitrust lawsuit against Pfizer in 2015, he spotted an opportunity to combat the state’s opioid epidemic.
Louisiana wants HHS head Price to sidestep Gilead hep C patents by Eric Sagonowsky Friday, May 5, 2017 Gilead Sciences could soon find itself facing yet another challenge, this time from the U.S. government.
